Testing a targeted radioactive drug for relapsed myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This Phase 1 study tests a targeted radioactive medicine made from daratumumab plus a radioactive payload, aiming to treat multiple myeloma that has come back or doesn’t respond to treatment. It’s designed mainly to check safety and how the treatment works in people who have had several prior therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 or older and able to give consent (or have a legal representative).
- Have multiple myeloma that can be measured in blood or urine, and you’ve received at least two prior treatment lines.
- You must have previously received: a proteasome inhibitor, an immune-modulating drug, and an anti-CD38 antibody (like daratumumab), and your disease must not have responded to daratumumab.
- Your myeloma cells must show CD38 on testing from a bone marrow sample (by flow test or tissue staining).
- Your body must be able to tolerate treatment: adequate blood counts, acceptable liver/kidney blood tests, and enough overall energy (Karnofsky score above 60%).
- You can’t have had daratumumab (or other anti-CD38 antibody) within the last 3 months, prior radiation with too much bone marrow exposure, or a history of radioactive (radiopharmaceutical) therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug for multiple myeloma that has come back or not responded to at least three previous treatments. It aims to see if the drug can help people whose cancer has progressed despite prior therapies including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody.
This trial tests a new approach: giving a targeted radioactive antibody (attached to a drug that finds CD38 on cancer cells) along with low-dose chemotherapy and targeted radiation to the bone marrow before a donor stem cell transplant. The goal is to prepare the body for the transplant while killing remaining cancer cells more precisely.
This trial tests a combination of two antibody drugs (elotuzumab and daratumumab) plus an oral pill (iberdomide) and a steroid (dexamethasone) for people whose multiple myeloma has come back after treatment. The goal is to see if this new mix works better than what's already available.
This trial tests whether a powerful new two-drug combo (daratumumab plus teclistamab) works better than the usual three-drug combos for people with high-risk multiple myeloma that has come back after just one prior treatment. If you’re in first relapse with high-risk features, this study could offer a promising new option.
This trial tests a new injected drug for people with multiple myeloma that has returned or stopped responding to at least 3 prior treatments. The goal is to see if the drug is safe and works against the cancer.
This trial tests a new medicine (GR1803) against a standard combination treatment for people whose multiple myeloma has come back or stopped responding to prior therapies. It aims to see if the new drug works better.
Hear when a new Recurrent Plasma Cell Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.